Linda Montgomery • January 10, 2024
Trial Participation- There is still time to join!

HCM Clinical Trial Opportunities 

We’ve been urging you to learn a few important points about your disease because HCM has various presentations and important metrics.

  • Are you obstructed or non-obstructed?
  • What is your Ejection Fraction – (EF)?
  • What is your NYHA functional class?
  • If you have a genetic mutation, if so, what is it?

Knowing the answers to these questions gives a healthcare provider a snapshot of your disease and also facilitates eligibility for clinical trials.  

Current trials:

  • The first is the Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy (ODYSSEY-HCM). For more information, please complete this survey: https://www.surveymonkey.com/r/pulse3
  • Other myosin inhibitor trials regarding the Efficacy and Safety of Aficamten. For information about this and other trials, please complete the survey: https://www.surveymonkey.com/r/pulselet6
  • MyPeak-1 is actively enrolling patients with nonobstructive HCM who have the MYBPC3 genetic mutation. For more information, please complete this survey: https://www.surveymonkey.com/r/peak10
  • For our younger HCM community members with the MYBPC3 gene, a study: Natural History Study in Pediatric Patients With MYBPC3 Mutation-associated Cardiomyopathy (MyCLIMB ).

If you are interested in any of these trial opportunities, please send me an email with your contact information – my email is linda@4hcm.org. 

If you haven’t gone through the HCMA Intake process within the last two years, please schedule an Intake Call on the website https://4hcm.org/education-and-support/. 

This will give us the best understanding of your current health, HCM presentation, and potential eligibility in upcoming trials.

HCMA Blog

Medical Management May

April 30, 2025
Medical Management means using medicines and other non-invasive therapies to relieve symptoms. It's exciting that new treatments for HCM are being studied and that the FDA approved Camzyos in 2022! HCM can cause various symptoms depending on how stiff the heart is, how much scarring (fibrosis) there is, and whether there is obstruction. Some people have no noticeable symptoms. Common symptoms are chest pain/pressure, shortness of breath, lightheadedness, fatigue, palpitations, and brain fog. Syncope (fainting) is dramatic but not as common as the other symptoms. Medications are the first-line treatment for symptoms of HCM. If patients can't take one class of medication, they can try a medication from a different class. Here are some medications used to treat HCM and what they're for: Beta Blockers - make your heart beat slower and relax better. They allow the heart to fill more completely between beats. They can lower blood pressure and relieve symptoms. Calcium Channel Blockers - used to lower blood pressure and slow the heart rate. May reduce symptoms from obstruction in HCM. Myosin Inhibitors - cause the heart to beat with less force. They may reduce obstruction and septal thickness in some patients. Camzyos (mavacamten) is the first of this class of medication. For more information, click HERE . Antiarrhythmics - help to restore normal rhythm in the heart. Blood Thinners - anticoagulants and anti-platelets make it harder for blood to clot. They are prescribed to reduce the risk of stroke. This risk is higher in patients with afib, aflutter, and artificial heart valves. Diuretics , or "water pills," help the kidneys get rid of extra water and salt, reducing swelling in the body. Sodium Channel Blockers - may reduce gradient in obstructive HCM and can treat chest pain. Some also act as antiarrhythmics. Antibiotics - treat or prevent bacterial infections. In HCM, they may be given before dental work to prevent infective endocarditis. To learn more and see the side effects of these medications, click HERE .
On a green background, a line drawing of a head that has complicated arrows pointing outwards

Decisions in HCM: Why are they so hard?

By Gordon Fox • April 25, 2025
Part 2 of a series on making decisions in HCM. A key reason is that decision making is so difficult is that most decisions involve more than one risk.
Hypertrophic Obsctructive Cardiomyopathy

Camzyos® receives manufacturing and marketing approval for HOCM in Japan

By Erica Friedman • April 22, 2025
Bristol Myers Squibb announces that Camzyos has been approved for Obstructive Hypertrophic Cardiomyopathy in Japan.
More Posts